Canine G-CSF polypeptides and pharmaceutical compositions comprising same
US5606024A · kind A · utility
13Cited by
2References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 1995 |
| Grant date | Feb 25, 1997 |
| Priority date | — |
| Expiry date | Apr 24, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods for treating or preventing infections in canine or feline animals which comprises administering an effective amount of granulocyte colony stimulating factor (G-CSF), are disclosed. The G-CSF may be naturally derived, or alternatively, the G-CSF and genetically engineered variants of G-CSF may be the expression products of genetically engineered prokaryotic or eukaryotic host cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.